← back to search

Maryam B. Lustberg

G1 Therapeutics (United States) · US
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Treatment and Pharmacology, Cancer survivorship and care, Cancer-related cognitive impairment studies, and Breast Cancer Treatment Studies.
h-index
52
citations
13,246
works
634
NIH funding
primary concept
Medicine
email

Recent publications

Breastfeeding after breast cancer in young <i>BRCA</i> carriers
JNCI Journal of the National Cancer Institute 2025cited by 4position: middledoi
The effect of using a large language model to respond to patient messages
The Lancet Digital Health 2024cited by 118position: middledoi
Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations
JCO Oncology Practice 2024cited by 37position: middledoi
Survivorship care for people affected by advanced or metastatic cancer: MASCC-ASCO standards and practice recommendations
Supportive Care in Cancer 2024cited by 30position: middledoi
The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
JCO Oncology Practice 2024cited by 28position: middledoi
A Randomized Trial of Hypofractionated Post-Mastectomy Radiation Therapy (PMRT) in Women with Breast Reconstruction (RT CHARM, Alliance A221505)
International Journal of Radiation Oncology*Biology*Physics 2024cited by 23position: middledoi
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2023cited by 126position: middledoi
Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
eLife 2023cited by 3position: middledoi
Clinical Characteristics, Racial Inequities, and Outcomes in Patients with Breast Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Cohort Study
medRxiv 2023cited by 0position: middledoi
Fear of Cancer Recurrence or Progression: What Is It and What Can We Do About It?
American Society of Clinical Oncology Educational Book 2022cited by 80position: lastdoi
A Narrative Review on the Collection and Use of Electronic Patient-Reported Outcomes in Cancer Survivorship Care with Emphasis on Symptom Monitoring
Current Oncology 2022cited by 56position: middledoi
Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients
Breast Cancer Research and Treatment 2022cited by 12position: lastdoi
Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium
Annals of Oncology 2021cited by 326position: middledoi
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
European Heart Journal 2021cited by 153position: middledoi
Targeting OCT3 attenuates doxorubicin-induced cardiac injury
Proceedings of the National Academy of Sciences 2021cited by 66position: middledoi
Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN)
Cancer Treatment Reviews 2021cited by 61position: lastdoi
Effects of tandem cognitive behavioral therapy and healthy lifestyle interventions on health-related outcomes in cancer survivors: a systematic review
Journal of Cancer Survivorship 2021cited by 24position: middledoi
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update
Journal of Clinical Oncology 2020cited by 1,028position: middledoi
Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group
Supportive Care in Cancer 2020cited by 142position: middledoi
Addressing the needs of cancer survivors during the COVID-19 pandemic
Journal of Cancer Survivorship 2020cited by 139position: middledoi
Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update
Blood Advances 2019cited by 162position: middledoi
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
Journal of Clinical Oncology 2019cited by 140position: middledoi
Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview
Supportive Care in Cancer 2019cited by 77position: lastdoi
Phase I Immunotherapy Trial with Two Chimeric HER-2 B-Cell Peptide Vaccines Emulsified in Montanide ISA 720VG and Nor-MDP Adjuvant in Patients with Advanced Solid Tumors
Clinical Cancer Research 2019cited by 65position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Charles L. Loprinzi · Mayo Clinic4 papers (2019–2021)Larissa Nekhlyudov · Harvard University3 papers (2020–2024)Raymond J. Chan · Flinders University3 papers (2022–2024)Bogda Koczwara · UNSW Sydney3 papers (2022–2024)Thomas J. Smith · West Virginia University3 papers (2020–2024)Alexandre Chan · University of California, Irvine3 papers (2019–2021)Daniel L. Hertz · MedStar Health3 papers (2019–2021)Hushan Yang · Thomas Jefferson University2 papers (2019–2019)Shivani Shinde · The University of Texas Health Science Center at Houston2 papers (2019–2020)Nicolas H. Hart · University of Technology Sydney2 papers (2024–2024) · 2 papers (2019–2020)Andrea L. Smith · Joint Base San Antonio2 papers (2024–2024)Jasmine Yee · The University of Sydney2 papers (2024–2024)Kari Bohlke · Northwell Health2 papers (2019–2019)Gregory B. Crawford · University of Auckland2 papers (2024–2024)Tiffany Tanaka · Sanford Consortium for Regenerative Medicine2 papers (2019–2019) · 2 papers (2024–2024)Chia Jie Tan · University of Utah2 papers (2019–2020)Ishwaria M. Subbiah · Sarah Cannon Research Institute2 papers (2019–2020) · 2 papers (2019–2019)